Although the retrospective design and the small number of cases constitute limitations, several reports have suggested the efficacy of switching to aflibercept in patients with wet AMD who were primarily or secondarily refractory to other anti-VEGF-A agents37, 38, 39. This evidence concerns the gene VEGFA and wet macular degeneration.